×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PAVM – pavmed inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PAVM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/26
06:43 am
pavm
PAVmed (NASDAQ:PAVM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
PAVmed (NASDAQ:PAVM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/13
11:37 am
pavm
PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/13
08:31 am
pavm
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]
Medium
Report
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]
11/13
08:00 am
pavm
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
Medium
Report
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
11/12
08:37 am
pavm
PAVmed Inc (PAVM) Q3 2025 Earnings Report Preview: What to Expect [Yahoo! Finance]
High
Report
PAVmed Inc (PAVM) Q3 2025 Earnings Report Preview: What to Expect [Yahoo! Finance]
11/12
08:19 am
pavm
PAVmed Non-GAAP EPS of -$0.10, revenue of $1.21M [Seeking Alpha]
High
Report
PAVmed Non-GAAP EPS of -$0.10, revenue of $1.21M [Seeking Alpha]
10/30
08:01 am
pavm
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
Medium
Report
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
10/11
06:14 am
pavm
PAVmed (NASDAQ:PAVM) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
High
Report
PAVmed (NASDAQ:PAVM) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/13
08:01 am
pavm
Form 8-K PAVmed Inc. For: Nov 13
Medium
Report
Form 8-K PAVmed Inc. For: Nov 13
11/12
05:23 pm
pavm
Form 10-Q PAVmed Inc. For: Sep 30
Medium
Report
Form 10-Q PAVmed Inc. For: Sep 30
10/31
04:05 pm
pavm
Form DEF 14A PAVmed Inc. For: Oct 31
Medium
Report
Form DEF 14A PAVmed Inc. For: Oct 31
10/20
06:48 pm
pavm
Form PRE 14A PAVmed Inc. For: Oct 20
Medium
Report
Form PRE 14A PAVmed Inc. For: Oct 20
10/2
04:22 pm
pavm
Form 4 PAVmed Inc. For: Sep 30 Filed by: Sparks Ronald M
Low
Report
Form 4 PAVmed Inc. For: Sep 30 Filed by: Sparks Ronald M
10/2
04:21 pm
pavm
Form 4 PAVmed Inc. For: Sep 30 Filed by: White Debra
Low
Report
Form 4 PAVmed Inc. For: Sep 30 Filed by: White Debra
10/2
04:20 pm
pavm
Form 4 PAVmed Inc. For: Sep 30 Filed by: Baxter Timothy E
Low
Report
Form 4 PAVmed Inc. For: Sep 30 Filed by: Baxter Timothy E
10/2
04:19 pm
pavm
Form 4 PAVmed Inc. For: Sep 30 Filed by: Glennon Michael J
Low
Report
Form 4 PAVmed Inc. For: Sep 30 Filed by: Glennon Michael J
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
PAVmed to Hold Business Update Conference Call on April 9, 2020
19.1%
3/30 Form NT 10-K PAVmed Inc. For: Dec 31 14.5%
4/9 PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update 14.2%
2/11 U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test 14.2%
4/21 PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device 11.5%
6/25 Form 8-K PAVmed Inc. For: Jun 25 10.6%
12/13 PAVmed Provides Update on CarpX™ Clinical Safety Study 9.4%
3/9 Form 8-K PAVmed Inc. For: Mar 09 8.9%
5/22 Form S-8 PAVmed Inc. 7.8%
3/2 PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients 7.1%
3/30 Form NT 10-K PAVmed Inc. For: Dec 31 14.5%
4/9 PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update 14.2%
2/11 U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test 14.2%
4/21 PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device 11.5%
6/25 Form 8-K PAVmed Inc. For: Jun 25 10.6%
12/13 PAVmed Provides Update on CarpX™ Clinical Safety Study 9.4%
3/9 Form 8-K PAVmed Inc. For: Mar 09 8.9%
5/22 Form S-8 PAVmed Inc. 7.8%
3/2 PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients 7.1%
TOP News Decliners
1/13
PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
-15.5%
11/5 PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization -12.5%
11/7 Form D PAVmed Inc. -10.9%
3/3 PAVmed Inc (NASDAQ: PAVM) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -10.2%
2/27 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -8.3%
4/18 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -7.7%
5/21 PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update -6.8%
6/24 PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™ -6.1%
5/1 Form 8-K PAVmed Inc. For: Apr 30 -6.0%
5/8 Form 424B5 PAVmed Inc. -5.9%
11/5 PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization -12.5%
11/7 Form D PAVmed Inc. -10.9%
3/3 PAVmed Inc (NASDAQ: PAVM) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -10.2%
2/27 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -8.3%
4/18 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -7.7%
5/21 PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update -6.8%
6/24 PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™ -6.1%
5/1 Form 8-K PAVmed Inc. For: Apr 30 -6.0%
5/8 Form 424B5 PAVmed Inc. -5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: